http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2863074-T3
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f751df1bae377eb002d83842ad010c12 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2405-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate | 2015-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fac4459bdceac791aa3880ccf2181e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8a1579625332df150a45600f4cfd39d |
publicationDate | 2021-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | ES-2863074-T3 |
titleOfInvention | Human monoclonal antibodies against ganglioside GD2 |
abstract | An isolated antibody or functional fragment thereof that binds GD2, wherein said antibody or functional fragment thereof comprises a combination of heavy chain variable domain (VH) and light chain variable domain (VL) selected from the following combinations ( i) to (viii): (i) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-109 of SEQ ID NO: 2, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-37, residues 55-57, and residues 94-102 of SEQ ID NO: 4; (ii) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-109 of SEQ ID NO: 6; and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-37, residues 55-57, and residues 94-102 of SEQ ID NO: 8; (iii) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-108 of SEQ ID NO: 10, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-38, residues 56-58, and residues 95-103 of SEQ ID NO: 12; (iv) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-109 of SEQ ID NO: 26, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-37, residues 55-57, and residues 94-102 of SEQ ID NO: 28; (v) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-108 of SEQ ID NO: 30, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-37, residues 55-57, and residues 94-102 of SEQ ID NO: 32; (vi) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-110 of SEQ ID NO: 34, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-32, residues 50-52, and residues 89-97 of SEQ ID NO: 38; (vii) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-110 of SEQ ID NO: 36, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-32, residues 50-52, and residues 89-97 of SEQ ID NO: 38; and (viii) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-108 of SEQ ID NO: 40, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-38, residues 56-58, and residues 95-103 of SEQ ID NO: 42. |
priorityDate | 2014-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1979.